Parisa Momtaz, MD
Medical Oncology · West Harrison, NYNPI 1811156052
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,865 of the $2,897 with a category attached, or 98.9%. E.r. Squibb & Sons, L.L.C. accounts for 98.9% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for medical oncology clinicians in NY, where the typical reported total is $4,912.
Across 2 payments — averaging $1448.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$3K
- GSK$32
Across 63 payments — averaging $5229.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$218K
- Karyopharm Therapeutics Inc.$112K
What the payments were for
- Consulting fees$2,86599%
- Education$321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 1 | $2,865 |
| GSK | 1 | $32 |
How this compares
$2,897 in reported general payments places this provider in the 45th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BraftoviEncorafenib | 44 | $663,834 |
| MektoviBinimetinib | 44 | $650,186 |
| MekinistTrametinib Dimethyl Sulfoxide | 31 | $565,664 |
| TafinlarDabrafenib Mesylate | 30 | $423,734 |
| ZarxioFilgrastim-Sndz | 11 | $18,313 |
| CreonLipase/Protease/Amylase | 13 | $17,211 |
| Ondansetron Hcl | 18 | $234 |
| Pantoprazole Sodium | 18 | $181 |
| Triamcinolone Acetonide | 11 | $178 |
| Prednisone | 33 | $58 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in West Harrison
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Maria TheodoulouAlbany$1.1M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
- Anthony MatoIthaca$909K
- Ehsan MalekBuffalo$826K
- Ghassan Abou-AlfaNew York$825K
- Miguel PeralesNew York$769K
- Komal JhaveriNew York$642K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.